Simon Haas

Group leader

Deutsches Krebsforschungszentrum
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

A balanced SUMOylation equilibrium safeguards the functional anti‐tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor‐immune synapse, we applied HLA class‐I‐targeted ligandomics and identified a function of activated SUMOylation in restricting the immunopeptidome landscape. Importantly, aberrant SUMOylation suppressed a unique HLA‐I peptide and oncoprotein‐derived neoepitope repertoire, enabling cancer cells to evade T cell immune surveillance. Mechanistically, SUMOylation impaired the immunoproteasome constitution and proteolytic activity, thus limiting the diversity of the peptide landscape. Further, SUMOylation altered TAP1 transporter binding preferences, thereby mimicking viral immune evasion strategies. As an actionable application, pharmacological inhibition of SUMOylation unmasked the targetable immunopeptidome, enhanced the tumor cell susceptibility to T cell killing and substantially reshaped the immune cell landscape. These findings highlight SUMOylation as a critical regulator of the adaptive anti‐tumor immune response. We propose SUMOylation inhibition as a strategy to enhance immunogenic peptide presentation, thereby improving the efficacy of cancer immunotherapies.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase. In contrast, reactivation of fetal genes in adult malignancies is considered a consequence of oncofetal reprogramming (OFR) and is associated with aggressive disease. By reconstructing epigenetic ontogeny in juvenile myelomonocytic leukemia (JMML), we identified a postnatal maturation state of JMML stem cells with high transcriptional plasticity indicative of OFR in high-risk disease. Similarly, postnatal activation of oncogenic signaling by inducible Ptpn11E76K mutation in mice triggered molecular plasticity and reactivation of fetal gene expression. Integrative multi-omics analysis revealed aberrant CD52 expression as a feature of high-risk JMML stem cells. Anti-CD52 treatment depleted JMML stem cells and blocked disease propagation in xenograft models. Our results challenge the prevailing maturation block model of pediatric leukemogenesis and establish RAS-associated stem cell plasticity as a determinant of OFR and potential therapeutic vulnerabilities in high-risk JMML. Significance: Persistent fetal gene expression in pediatric malignancies is considered a consequence of prenatal maturation blockade. In this study, we demonstrate that oncogenic PTPN11 mutations enhance cellular plasticity. This leads to partial restoration of fetal molecular programs, creating new therapeutically exploitable vulnerabilities. See commentary by Miao and Xu, pp. XX.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (33)

Gerald Willimsky

Professor

Charité - Universitätsmedizin Berlin

GERMANY
View details

Fredrik Swartling

SciLifeLab Group Leader; Director of the Preclinical Cancer Treatment (PCT) Center

Uppsala University

SWEDEN
View details

Maja C Funk

Junior Group Leader

Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit

GERMANY
View details

Michael Korenkov

Charité - Universitätsmedizin Berlin

GERMANY
View details

Hans Binder

Managing Director

Leipzig University

GERMANY
View details

Anja E. Hauser

-

GERMANY
View details

Antigoni Triantafyllopoulou

Prof. Dr.

Charité - Universitätsmedizin Berlin

GERMANY
View details

Gerrit Wolters-Eisfeld

University Medical Center Hamburg-Eppendorf

GERMANY
View details

Ulrich Keller

Prof. Dr.

Charité - Universitätsmedizin Berlin

GERMANY
View details

Martin Klatt

Charité - Universitätsmedizin Berlin

GERMANY
View details

Jan Krönke

Professor

Charité - Universitätsmedizin Berlin

GERMANY
View details

Daniel Hübschmann

Research Group Leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Stefan Müller

Goethe University Frankfurt

GERMANY
View details

Silvana Libertini

Lab head

Novartis Institutes for BioMedical Research Basel

SWITZERLAND
View details

Christian H. Bucher

Charité - Universitätsmedizin Berlin

GERMANY
View details

Florian Kurth

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY
View details

Lukas John

Deutsches Krebsforschungszentrum

GERMANY
View details

Jessica Taylor

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Kai Tan

Professor

University of Pennsylvania

UNITED STATES
View details

Julia E. Neumann

Prof. Dr. med

University Medical Center Hamburg-Eppendorf

GERMANY
View details

Francis Baumgartner

Charité - Universitätsmedizin Berlin

GERMANY
View details

Sandy Kroh

Charité - Universitätsmedizin Berlin

GERMANY
View details

Jonathan Seidman

Professor

Harvard University

UNITED STATES
View details

Henry Loeffler-Wirth

Research group leader

Leipzig University

GERMANY
View details

Michael Hundemer

Professor

University Hospital Heidelberg

GERMANY
View details

Ingram Iaccarino

Scientist

Kiel University

GERMANY
View details

Carsten Watzl

Scientific Director

Leibniz-Institut für Arbeitsforschung an der TU Dortmund

GERMANY
View details

Karsten Rippe

Head of Division

German Cancer Research Center (DKFZ)

GERMANY
View details

Carsten Müller-Tidow

Medical Director

University Hospital Heidelberg

GERMANY
View details

Helene Kretzmer

Professor and Chair Computational Genomics

Hasso Plattner Institute

GERMANY
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details

Judith B. Zaugg

University of Basel

SWITZERLAND
View details

Birgit Sawitzki

University Professor

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details